Lin Cheng-Chieh, Wu Hsi-Chin, Chen Wen-Chi, Chen Huey-Yi, Tsai Fuu-Jen
Department of Family Medicine, China Medical College Hospital, China Medical College, Taichung, Taiwan.
Urol Oncol. 2003 Jul-Aug;21(4):262-5. doi: 10.1016/s1078-1439(02)00276-4.
Prostate cancer is the most common urological malignancy in Taiwan. The formation of prostate cancer has been reported to be associated with androgen. Two key steps in the sex steroid synthesis are mediated by the enzyme cytochrome p450c17alpha which is encoded in the CYP17 gene. Our aim was to investigate whether a polymorphism of CYP17 gene could be used as a genetic marker for associating prostate cancer. In this study, we compared the frequency of the C/T polymorphism of CYP17 gene 5'-UTR promoter region between 93 patients with prostate cancer and 121 healthy male volunteers (age, >60 years). The result revealed no significant association between the CYP17 genotype and prostate cancer (P =.781). Therefore, CYP17 C/T polymorphism is not a valid genetic marker for prostate cancer. Although a possible interaction between CYP17 gene C/T polymorphism and SP-1 transcription factor has been reported in the literature, we did not find any evidence for this the difference among clinical staging, pathological grading, or responsiveness to hormonal therapy in prostate cancer.
前列腺癌是台湾最常见的泌尿系统恶性肿瘤。据报道，前列腺癌的形成与雄激素有关。性类固醇合成中的两个关键步骤由细胞色素p450c17α酶介导，该酶由CYP17基因编码。我们的目的是研究CYP17基因的多态性是否可作为与前列腺癌相关的遗传标记。在本研究中，我们比较了93例前列腺癌患者和121名健康男性志愿者（年龄>60岁）之间CYP17基因5'-UTR启动子区域C/T多态性的频率。结果显示CYP17基因型与前列腺癌之间无显著关联（P = 0.781）。因此，CYP17 C/T多态性不是前列腺癌的有效遗传标记。尽管文献中报道了CYP17基因C/T多态性与SP-1转录因子之间可能存在相互作用，但我们未发现前列腺癌临床分期、病理分级或激素治疗反应性之间存在任何差异的证据。
